世界の卵巣癌治療＆診断市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Therapies and Diagnostics for Ovarian Cancer Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4951 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、卵巣癌治療＆診断の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（手術、放射線療法、薬物治療）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・卵巣癌治療＆診断の市場動向 ・企業の競争状況、市場シェア ・卵巣癌治療＆診断の種類別市場規模と予測2016-2027（手術、放射線療法、薬物治療） ・卵巣癌治療＆診断の用途別市場規模と予測2016-2027（病院、診療所、その他） ・卵巣癌治療＆診断の北米市場規模2016-2027（アメリカ、カナダ） ・卵巣癌治療＆診断の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・卵巣癌治療＆診断のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・卵巣癌治療＆診断の中南米市場規模2016-2027（メキシコ、ブラジル） ・卵巣癌治療＆診断の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Astra Zeneca、Clovis Oncology、Myriad、TESARO、AbbVie Inc、Celgene、Janssen Pharmaceuticals、Merck、Novartis AG、Quest Diagnostics Inc） ・結論

Ovarian cancer (ovarian cancer) accounts for 2.4% ~ 6.5% of the common malignant tumors in women, and ranks the third among the cancers of the female reproductive system, secondary to cervical cancer and uterine body cancer.In recent years, due to the prevention and treatment of cervical cancer and uterine body cancer, some achievements have been made, while the prevention and treatment of ovarian cancer is relatively small.So ovarian cancer is the leading cause of death among cancers of the reproductive system in women.

Market Analysis and Insights: Global Therapies and Diagnostics for Ovarian Cancer Market
The global Therapies and Diagnostics for Ovarian Cancer market size is projected to reach US$ 2713.5 million by 2027, from US$ 1997.1 million in 2020, at a CAGR of 4.0% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Therapies and Diagnostics for Ovarian Cancer market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Therapies and Diagnostics for Ovarian Cancer market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Therapies and Diagnostics for Ovarian Cancer market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Therapies and Diagnostics for Ovarian Cancer market.

Global Therapies and Diagnostics for Ovarian Cancer Scope and Market Size
Therapies and Diagnostics for Ovarian Cancer market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Therapies and Diagnostics for Ovarian Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Surgery
Radiation Therapy
Drug Treatment

Segment by Application
Hospitals
Clinics
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Astra Zeneca
Clovis Oncology
Myriad
TESARO
AbbVie Inc
Celgene
Janssen Pharmaceuticals
Merck
Novartis AG
Quest Diagnostics Inc

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Therapies and Diagnostics for Ovarian Cancer Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Surgery
1.2.3 Radiation Therapy
1.2.4 Drug Treatment
1.3 Market by Application
1.3.1 Global Therapies and Diagnostics for Ovarian Cancer Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Therapies and Diagnostics for Ovarian Cancer Market Perspective (2016-2027)
2.2 Therapies and Diagnostics for Ovarian Cancer Growth Trends by Regions
2.2.1 Therapies and Diagnostics for Ovarian Cancer Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Therapies and Diagnostics for Ovarian Cancer Historic Market Share by Regions (2016-2021)
2.2.3 Therapies and Diagnostics for Ovarian Cancer Forecasted Market Size by Regions (2022-2027)
2.3 Therapies and Diagnostics for Ovarian Cancer Industry Dynamic
2.3.1 Therapies and Diagnostics for Ovarian Cancer Market Trends
2.3.2 Therapies and Diagnostics for Ovarian Cancer Market Drivers
2.3.3 Therapies and Diagnostics for Ovarian Cancer Market Challenges
2.3.4 Therapies and Diagnostics for Ovarian Cancer Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Therapies and Diagnostics for Ovarian Cancer Players by Revenue
3.1.1 Global Top Therapies and Diagnostics for Ovarian Cancer Players by Revenue (2016-2021)
3.1.2 Global Therapies and Diagnostics for Ovarian Cancer Revenue Market Share by Players (2016-2021)
3.2 Global Therapies and Diagnostics for Ovarian Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Therapies and Diagnostics for Ovarian Cancer Revenue
3.4 Global Therapies and Diagnostics for Ovarian Cancer Market Concentration Ratio
3.4.1 Global Therapies and Diagnostics for Ovarian Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Therapies and Diagnostics for Ovarian Cancer Revenue in 2020
3.5 Therapies and Diagnostics for Ovarian Cancer Key Players Head office and Area Served
3.6 Key Players Therapies and Diagnostics for Ovarian Cancer Product Solution and Service
3.7 Date of Enter into Therapies and Diagnostics for Ovarian Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Therapies and Diagnostics for Ovarian Cancer Breakdown Data by Type
4.1 Global Therapies and Diagnostics for Ovarian Cancer Historic Market Size by Type (2016-2021)
4.2 Global Therapies and Diagnostics for Ovarian Cancer Forecasted Market Size by Type (2022-2027)

5 Therapies and Diagnostics for Ovarian Cancer Breakdown Data by Application
5.1 Global Therapies and Diagnostics for Ovarian Cancer Historic Market Size by Application (2016-2021)
5.2 Global Therapies and Diagnostics for Ovarian Cancer Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Therapies and Diagnostics for Ovarian Cancer Market Size (2016-2027)
6.2 North America Therapies and Diagnostics for Ovarian Cancer Market Size by Type
6.2.1 North America Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2016-2021)
6.2.2 North America Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2022-2027)
6.2.3 North America Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2016-2027)
6.3 North America Therapies and Diagnostics for Ovarian Cancer Market Size by Application
6.3.1 North America Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2016-2021)
6.3.2 North America Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2022-2027)
6.3.3 North America Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2016-2027)
6.4 North America Therapies and Diagnostics for Ovarian Cancer Market Size by Country
6.4.1 North America Therapies and Diagnostics for Ovarian Cancer Market Size by Country (2016-2021)
6.4.2 North America Therapies and Diagnostics for Ovarian Cancer Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Therapies and Diagnostics for Ovarian Cancer Market Size (2016-2027)
7.2 Europe Therapies and Diagnostics for Ovarian Cancer Market Size by Type
7.2.1 Europe Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2016-2021)
7.2.2 Europe Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2022-2027)
7.2.3 Europe Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2016-2027)
7.3 Europe Therapies and Diagnostics for Ovarian Cancer Market Size by Application
7.3.1 Europe Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2016-2021)
7.3.2 Europe Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2022-2027)
7.3.3 Europe Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2016-2027)
7.4 Europe Therapies and Diagnostics for Ovarian Cancer Market Size by Country
7.4.1 Europe Therapies and Diagnostics for Ovarian Cancer Market Size by Country (2016-2021)
7.4.2 Europe Therapies and Diagnostics for Ovarian Cancer Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Size (2016-2027)
8.2 Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Size by Type
8.2.1 Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2016-2027)
8.3 Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Size by Application
8.3.1 Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2016-2027)
8.4 Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Size by Region
8.4.1 Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Therapies and Diagnostics for Ovarian Cancer Market Size (2016-2027)
9.2 Latin America Therapies and Diagnostics for Ovarian Cancer Market Size by Type
9.2.1 Latin America Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2016-2021)
9.2.2 Latin America Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2022-2027)
9.2.3 Latin America Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2016-2027)
9.3 Latin America Therapies and Diagnostics for Ovarian Cancer Market Size by Application
9.3.1 Latin America Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2016-2021)
9.3.2 Latin America Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2022-2027)
9.3.3 Latin America Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2016-2027)
9.4 Latin America Therapies and Diagnostics for Ovarian Cancer Market Size by Country
9.4.1 Latin America Therapies and Diagnostics for Ovarian Cancer Market Size by Country (2016-2021)
9.4.2 Latin America Therapies and Diagnostics for Ovarian Cancer Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Size (2016-2027)
10.2 Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Size by Type
10.2.1 Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2016-2027)
10.3 Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Size by Application
10.3.1 Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2016-2027)
10.4 Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Size by Country
10.4.1 Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Astra Zeneca
11.1.1 Astra Zeneca Company Details
11.1.2 Astra Zeneca Business Overview
11.1.3 Astra Zeneca Therapies and Diagnostics for Ovarian Cancer Introduction
11.1.4 Astra Zeneca Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021)
11.1.5 Astra Zeneca Recent Development
11.2 Clovis Oncology
11.2.1 Clovis Oncology Company Details
11.2.2 Clovis Oncology Business Overview
11.2.3 Clovis Oncology Therapies and Diagnostics for Ovarian Cancer Introduction
11.2.4 Clovis Oncology Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021)
11.2.5 Clovis Oncology Recent Development
11.3 Myriad
11.3.1 Myriad Company Details
11.3.2 Myriad Business Overview
11.3.3 Myriad Therapies and Diagnostics for Ovarian Cancer Introduction
11.3.4 Myriad Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021)
11.3.5 Myriad Recent Development
11.4 TESARO
11.4.1 TESARO Company Details
11.4.2 TESARO Business Overview
11.4.3 TESARO Therapies and Diagnostics for Ovarian Cancer Introduction
11.4.4 TESARO Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021)
11.4.5 TESARO Recent Development
11.5 AbbVie Inc
11.5.1 AbbVie Inc Company Details
11.5.2 AbbVie Inc Business Overview
11.5.3 AbbVie Inc Therapies and Diagnostics for Ovarian Cancer Introduction
11.5.4 AbbVie Inc Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021)
11.5.5 AbbVie Inc Recent Development
11.6 Celgene
11.6.1 Celgene Company Details
11.6.2 Celgene Business Overview
11.6.3 Celgene Therapies and Diagnostics for Ovarian Cancer Introduction
11.6.4 Celgene Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021)
11.6.5 Celgene Recent Development
11.7 Janssen Pharmaceuticals
11.7.1 Janssen Pharmaceuticals Company Details
11.7.2 Janssen Pharmaceuticals Business Overview
11.7.3 Janssen Pharmaceuticals Therapies and Diagnostics for Ovarian Cancer Introduction
11.7.4 Janssen Pharmaceuticals Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021)
11.7.5 Janssen Pharmaceuticals Recent Development
11.8 Merck
11.8.1 Merck Company Details
11.8.2 Merck Business Overview
11.8.3 Merck Therapies and Diagnostics for Ovarian Cancer Introduction
11.8.4 Merck Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021)
11.8.5 Merck Recent Development
11.9 Novartis AG
11.9.1 Novartis AG Company Details
11.9.2 Novartis AG Business Overview
11.9.3 Novartis AG Therapies and Diagnostics for Ovarian Cancer Introduction
11.9.4 Novartis AG Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021)
11.9.5 Novartis AG Recent Development
11.10 Quest Diagnostics Inc
11.10.1 Quest Diagnostics Inc Company Details
11.10.2 Quest Diagnostics Inc Business Overview
11.10.3 Quest Diagnostics Inc Therapies and Diagnostics for Ovarian Cancer Introduction
11.10.4 Quest Diagnostics Inc Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021)
11.10.5 Quest Diagnostics Inc Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Therapies and Diagnostics for Ovarian Cancer Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Surgery
Table 3. Key Players of Radiation Therapy
Table 4. Key Players of Drug Treatment
Table 5. Global Therapies and Diagnostics for Ovarian Cancer Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Therapies and Diagnostics for Ovarian Cancer Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Therapies and Diagnostics for Ovarian Cancer Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Therapies and Diagnostics for Ovarian Cancer Market Share by Regions (2016-2021)
Table 9. Global Therapies and Diagnostics for Ovarian Cancer Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Therapies and Diagnostics for Ovarian Cancer Market Share by Regions (2022-2027)
Table 11. Therapies and Diagnostics for Ovarian Cancer Market Trends
Table 12. Therapies and Diagnostics for Ovarian Cancer Market Drivers
Table 13. Therapies and Diagnostics for Ovarian Cancer Market Challenges
Table 14. Therapies and Diagnostics for Ovarian Cancer Market Restraints
Table 15. Global Therapies and Diagnostics for Ovarian Cancer Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Therapies and Diagnostics for Ovarian Cancer Market Share by Players (2016-2021)
Table 17. Global Top Therapies and Diagnostics for Ovarian Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Therapies and Diagnostics for Ovarian Cancer as of 2020)
Table 18. Ranking of Global Top Therapies and Diagnostics for Ovarian Cancer Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Therapies and Diagnostics for Ovarian Cancer Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Therapies and Diagnostics for Ovarian Cancer Product Solution and Service
Table 22. Date of Enter into Therapies and Diagnostics for Ovarian Cancer Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Therapies and Diagnostics for Ovarian Cancer Revenue Market Share by Type (2016-2021)
Table 26. Global Therapies and Diagnostics for Ovarian Cancer Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Therapies and Diagnostics for Ovarian Cancer Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Therapies and Diagnostics for Ovarian Cancer Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Therapies and Diagnostics for Ovarian Cancer Revenue Market Share by Application (2016-2021)
Table 30. Global Therapies and Diagnostics for Ovarian Cancer Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Therapies and Diagnostics for Ovarian Cancer Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Therapies and Diagnostics for Ovarian Cancer Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Therapies and Diagnostics for Ovarian Cancer Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Therapies and Diagnostics for Ovarian Cancer Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Therapies and Diagnostics for Ovarian Cancer Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Therapies and Diagnostics for Ovarian Cancer Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Therapies and Diagnostics for Ovarian Cancer Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Size by Country (2022-2027) & (US$ Million)
Table 62. Astra Zeneca Company Details
Table 63. Astra Zeneca Business Overview
Table 64. Astra Zeneca Therapies and Diagnostics for Ovarian Cancer Product
Table 65. Astra Zeneca Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021) & (US$ Million)
Table 66. Astra Zeneca Recent Development
Table 67. Clovis Oncology Company Details
Table 68. Clovis Oncology Business Overview
Table 69. Clovis Oncology Therapies and Diagnostics for Ovarian Cancer Product
Table 70. Clovis Oncology Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021) & (US$ Million)
Table 71. Clovis Oncology Recent Development
Table 72. Myriad Company Details
Table 73. Myriad Business Overview
Table 74. Myriad Therapies and Diagnostics for Ovarian Cancer Product
Table 75. Myriad Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021) & (US$ Million)
Table 76. Myriad Recent Development
Table 77. TESARO Company Details
Table 78. TESARO Business Overview
Table 79. TESARO Therapies and Diagnostics for Ovarian Cancer Product
Table 80. TESARO Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021) & (US$ Million)
Table 81. TESARO Recent Development
Table 82. AbbVie Inc Company Details
Table 83. AbbVie Inc Business Overview
Table 84. AbbVie Inc Therapies and Diagnostics for Ovarian Cancer Product
Table 85. AbbVie Inc Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021) & (US$ Million)
Table 86. AbbVie Inc Recent Development
Table 87. Celgene Company Details
Table 88. Celgene Business Overview
Table 89. Celgene Therapies and Diagnostics for Ovarian Cancer Product
Table 90. Celgene Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021) & (US$ Million)
Table 91. Celgene Recent Development
Table 92. Janssen Pharmaceuticals Company Details
Table 93. Janssen Pharmaceuticals Business Overview
Table 94. Janssen Pharmaceuticals Therapies and Diagnostics for Ovarian Cancer Product
Table 95. Janssen Pharmaceuticals Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021) & (US$ Million)
Table 96. Janssen Pharmaceuticals Recent Development
Table 97. Merck Company Details
Table 98. Merck Business Overview
Table 99. Merck Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021) & (US$ Million)
Table 100. Merck Recent Development
Table 101. Novartis AG Company Details
Table 102. Novartis AG Business Overview
Table 103. Novartis AG Therapies and Diagnostics for Ovarian Cancer Product
Table 104. Novartis AG Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021) & (US$ Million)
Table 105. Novartis AG Recent Development
Table 106. Quest Diagnostics Inc Company Details
Table 107. Quest Diagnostics Inc Business Overview
Table 108. Quest Diagnostics Inc Therapies and Diagnostics for Ovarian Cancer Product
Table 109. Quest Diagnostics Inc Revenue in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021) & (US$ Million)
Table 110. Quest Diagnostics Inc Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Therapies and Diagnostics for Ovarian Cancer Market Share by Type: 2020 VS 2027
Figure 2. Surgery Features
Figure 3. Radiation Therapy Features
Figure 4. Drug Treatment Features
Figure 5. Global Therapies and Diagnostics for Ovarian Cancer Market Share by Application: 2020 VS 2027
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Others Case Studies
Figure 9. Therapies and Diagnostics for Ovarian Cancer Report Years Considered
Figure 10. Global Therapies and Diagnostics for Ovarian Cancer Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Therapies and Diagnostics for Ovarian Cancer Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Therapies and Diagnostics for Ovarian Cancer Market Share by Regions: 2020 VS 2027
Figure 13. Global Therapies and Diagnostics for Ovarian Cancer Market Share by Regions (2022-2027)
Figure 14. Global Therapies and Diagnostics for Ovarian Cancer Market Share by Players in 2020
Figure 15. Global Top Therapies and Diagnostics for Ovarian Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Therapies and Diagnostics for Ovarian Cancer as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Therapies and Diagnostics for Ovarian Cancer Revenue in 2020
Figure 17. Global Therapies and Diagnostics for Ovarian Cancer Revenue Market Share by Type (2016-2021)
Figure 18. Global Therapies and Diagnostics for Ovarian Cancer Revenue Market Share by Type (2022-2027)
Figure 19. North America Therapies and Diagnostics for Ovarian Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Therapies and Diagnostics for Ovarian Cancer Market Share by Type (2016-2027)
Figure 21. North America Therapies and Diagnostics for Ovarian Cancer Market Share by Application (2016-2027)
Figure 22. North America Therapies and Diagnostics for Ovarian Cancer Market Share by Country (2016-2027)
Figure 23. United States Therapies and Diagnostics for Ovarian Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Therapies and Diagnostics for Ovarian Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Therapies and Diagnostics for Ovarian Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Therapies and Diagnostics for Ovarian Cancer Market Share by Type (2016-2027)
Figure 27. Europe Therapies and Diagnostics for Ovarian Cancer Market Share by Application (2016-2027)
Figure 28. Europe Therapies and Diagnostics for Ovarian Cancer Market Share by Country (2016-2027)
Figure 29. Germany Therapies and Diagnostics for Ovarian Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Therapies and Diagnostics for Ovarian Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Therapies and Diagnostics for Ovarian Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Therapies and Diagnostics for Ovarian Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Therapies and Diagnostics for Ovarian Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Therapies and Diagnostics for Ovarian Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Therapies and Diagnostics for Ovarian Cancer Market Share by Region (2016-2027)
Figure 39. China Therapies and Diagnostics for Ovarian Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Therapies and Diagnostics for Ovarian Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Therapies and Diagnostics for Ovarian Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Therapies and Diagnostics for Ovarian Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Therapies and Diagnostics for Ovarian Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Therapies and Diagnostics for Ovarian Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Therapies and Diagnostics for Ovarian Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Therapies and Diagnostics for Ovarian Cancer Market Share by Type (2016-2027)
Figure 47. Latin America Therapies and Diagnostics for Ovarian Cancer Market Share by Application (2016-2027)
Figure 48. Latin America Therapies and Diagnostics for Ovarian Cancer Market Share by Country (2016-2027)
Figure 49. Mexico Therapies and Diagnostics for Ovarian Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Therapies and Diagnostics for Ovarian Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Market Share by Country (2016-2027)
Figure 55. Turkey Therapies and Diagnostics for Ovarian Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Therapies and Diagnostics for Ovarian Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Therapies and Diagnostics for Ovarian Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Astra Zeneca Revenue Growth Rate in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021)
Figure 59. Clovis Oncology Revenue Growth Rate in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021)
Figure 60. Myriad Revenue Growth Rate in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021)
Figure 61. TESARO Revenue Growth Rate in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021)
Figure 62. AbbVie Inc Revenue Growth Rate in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021)
Figure 63. Celgene Revenue Growth Rate in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021)
Figure 64. Janssen Pharmaceuticals Revenue Growth Rate in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021)
Figure 65. Merck Revenue Growth Rate in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021)
Figure 66. Novartis AG Revenue Growth Rate in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021)
Figure 67. Quest Diagnostics Inc Revenue Growth Rate in Therapies and Diagnostics for Ovarian Cancer Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

---